Journal of International Oncology ›› 2024, Vol. 51 ›› Issue (3): 166-169.doi: 10.3760/cma.j.cn371439-20231130-00026

• Reviews • Previous Articles     Next Articles

Imaging diagnosis, pathological upgrade, and imaging technology progress of ductal carcinoma in situ of the breast

Zhang Lili1, Tan Ru2, Fang Xueli1, Yang Yu1, Sang Zheng1, Li Baosheng1()   

  1. 1Department of Radiation Oncology, Cancer Hospital Affiliated to Shandong First Medical University, Jinan 250117, China
    2Department of Imaging, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
  • Received:2023-11-30 Revised:2023-12-26 Online:2024-03-08 Published:2024-04-10
  • Contact: Li Baosheng, Email: baoshli1963@163.com

Abstract:

Ductal carcinoma in situ of the breast (DCIS) most commonly manifests as asymptomatic calcifications at mammography. The most common manifestation of MRI is nonmass enhancement. The ultrasound mainly presents as a hypoechoic irregular hypervascular mass without posterior features. Core-needle biopsy is a commonly used method for preoperative diagnosis of DCIS. Due to differences in needle type and sample size, there is a certain degree of pathological upgrading of the lesion. In recent years, there has been controversy over the diagnosis and treatment of DCIS. With the development of breast disease diagnostic technology, advances in digital breast tomography, artificial intelligence, and radiomics are expected to help DCIS management and address issues such as overdiagnosis.

Key words: Carcinoma, intraductal, noninfiltrating, Imaging diagnosis, Pathology upgrade